Aquestive Therapeutics, Inc.

AQST

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001398733

SEC filings (opens in a new tab)

In the last 90 days, Aquestive Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 185 institutions reported holding it in 13F filings for Q2 2026, worth $299.5M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Aquestive Therapeutics, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023 All holders in Q3 2023

13F holders of AQST: Q3 2023 compared with Q4 2023
Measure	Q3 2023	Q4 2023	Change
Holders	48	57	+9
Shares	22.9M	23.8M	+938.4K (+4.1%)
Value	$21.5M	$48.1M	+$26.5M (+123.3%)

New holders (15)

Institutions that held Aquestive Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to AQST in Q4 2023
Institution	Shares	Value	% of portfolio
Essex Investment Management Co LLC	846,167	$1.71M	0.34%
Legato Capital Management LLC	340,564	$687.9K	0.09%
Jane Street Group, LLC	156,085	$315.3K	0.00%
683 Capital Management, LLC	93,510	$188.9K	0.02%
Citigroup Inc	82,177	$166.0K	0.00%
Boothbay Fund Management, LLC	34,985	$70.7K	0.00%
Virtu Financial LLC	32,170	$65.0K	0.01%
Goldman Sachs Group Inc	30,499	$61.6K	0.00%
Jump Financial, LLC	29,812	$60.2K	0.00%
ExodusPoint Capital Management, LP	26,079	$53.0K	0.00%
Y-Intercept (Hong Kong) Ltd	23,572	$47.6K	0.00%
Trust Point Inc.	10,045	$20.3K	0.00%
Bank of America Corp	8,712	$17.6K	0.00%
UBS Group AG	2,290	$4.63K	0.00%
Parallel Advisors, LLC	100	$202	0.00%

Sold out (6)

Institutions that held Aquestive Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.

Institutions that sold out of AQST in Q4 2023
Institution	Shares, Q3 2023	Value, Q3 2023
Gsa Capital Partners LLP	100,854	$154.0K
Squarepoint Ops LLC	75,683	$115.8K
XTX Topco Ltd	52,980	$81.1K
Man Group plc	–	$66.7K
Heron Bay Capital Management	14,025	$21.5K
Barclays PLC	7,144	$10.9K